The FDA has authorized the emergency use of the antibody cocktail given to U.S. President Donald Trump after infection with coronavirus.
The Regeneron experimental treatment will now be used for patients with COVID-19 with a high risk of severe disease. On Saturday, U.S. health officials agreed to allow the emergency use of a second antibody-based drug to help the immune system fight COVID-19. The president received this drug last month when he was ill.
The drug is prescribed once through an I.V. drip. The administration has authorized its use for adults and children 12 years and older who weigh at least 40 kilograms and are at high risk of serious COVID-19 disease due to age or certain diseases. The first results show that the drug can reduce the number of hospitalizations 9 or visits to emergency departments in patients with a high risk of disease progression, the agency said.
Regeneron will be available to approximately 300,000 patients in the near future.